Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2019 05:00 ET | Source: Biogen Inc.

New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatmentLatest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and...
August 20, 2019 07:30 ET | Source: Biogen Inc.; Invitae Corporation

Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients

New SMA STAT genetic test reduces time to provide results from 21 to four days to aid in clinical careEarly treatment of SMA has been shown to slow disease progression and improve or stabilize loss of...
July 30, 2019 07:30 ET | Source: Biogen Inc.

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis

— Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study’s Primary Endpoint Assessing Self-Reported GI Events — — Discontinuations Due to GI...
July 01, 2019 07:30 ET | Source: Biogen Inc.

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

New results from the NURTURE study demonstrate that pre-symptomatic infants treated with SPINRAZA are achieving motor milestones that are unprecedented in the natural history of the disease, including...
June 29, 2019 04:00 ET | Source: Biogen Inc.

Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy

Label update includes data from four clinical studies including long-term safety and efficacy data across a broad Spinal Muscular Atrophy (SMA) populationData from over 300 patients across a broad...
June 11, 2019 19:05 ET | Source: Biogen Inc.

Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019

Data to be presented at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high adherence of patients to...
June 07, 2019 05:41 ET | Source: Biogen Inc.

Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced that it has completed its acquisition of Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene...
May 30, 2019 07:30 ET | Source: Biogen Inc.

New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis

Diroximel fumarate significantly reduced disease activity in newly diagnosed relapsing multiple sclerosis (MS) patients and those previously treated with interferons or glatiramer acetate Data show...
May 20, 2019 07:30 ET | Source: Biogen Inc.

Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation

CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation (TRC Capital)...
May 14, 2019 19:02 ET | Source: Biogen Inc.

Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy

SPINRAZA becomes the first therapy recommended in the United Kingdom for 5q spinal muscular atrophy to treat all age groups, including patients who are pre-symptomaticMore than 7,500 individuals have...